Skip to main content

Table 3 Dyspnea Evaluation Based on NYHA classification on Study Days 1 and 14

From: Efficacy and safety of Levamisole treatment in clinical presentations of non-hospitalized patients with COVID-19: a double-blind, randomized, controlled trial

NYHA Class

Placebo/Routine Care

Levamisole/ Routine Care

Day 1

Day 14

Day 1

Day 14

N (%)

N (%)

Class I (Mild)

12

0

11

0

Class II (Mild)

0

0

0

0

Class III (Moderate)

8

4

8

0

Class IV (Severe)

5

3

6

0

  1. Class I: No limitation of physical activity; Class II: Slight limitation of physical activity; Class III: Marked limitation of physical activity; Class IV: Unable to carry on any physical activity without discomfort [20]